Webinar
Overcoming challenges in drug metabolism: in silico approaches
Recorded
Interpreting metabolite-ID experiments; determining the right species for animal studies; providing optimisation suggestions for your medicinal chemistry colleagues to overcome metabolism issues – these are just a few of the challenging tasks assigned to DMPK scientists. How can we best tackle these to ensure the success of our drug discovery projects?
Watch Optibrium CEO, Dr Matthew Segall, on 12 March as he explored Optibrium’s past seven years of metabolism prediction research, and demonstrates how in silico modelling techniques can support DMPK scientists in their workflows.
The webinar covers:
- The drug metabolism challenges that might be faced by DMPK scientists
- The application of in silico modelling methods to target these challenges, including state-of-the-art quantum mechanical and machine learning models
- A demonstration of our latest software, Semeta™ , an in silico metabolism prediction platform tailored specifically for DMPK scientists
Complete the form to watch the recording
Meet the speakers
Matthew Segall PhD
CEO and Company Director
Matt has a Master of Science in computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.